Glycosylated antitumor ether lipids as novel cancer stem cell cytotoxic agents

Patent metadata

Field	Value
Publication number	US-11261210-B2
Application number	US-201314377551-A
Country	US
Kind code	B2
Filing date	Feb 8, 2013
Priority date	Feb 8, 2012
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

Glycosylated antitumor ether lipids (GAELs) are effective cytotoxic agents against cancer stem cells. Furthermore, combining GAELs which kill cells by a caspase-independent pathway with agents that kill cells by apoptosis will lead to elimination of the differentiated tumor cells and the undifferentiated cancer stem cells leading to an elimination of the tumor and preventing recurrence.

First claim

The invention claimed is:

1. A method of treating a cancer that is refractory to treatment with existing apoptosis-inducing agents comprising administering to an individual having a cancer comprising cancer stem cells that are refractory to treatment with existing apoptosis-inducing agents an effective amount of a compound selected from the group consisting of:

said compound inhibiting development of the cancer stem cells into tumorspheres and causing the disintegration of the cancer stem cells, thereby causing total loss of viability of the cancer stem cells in the individual.

2. The method according to claim 1 wherein the compound is selected from the group consisting of:

3. The method according to claim 2 wherein the cancer is selected from the group consisting of breast cancer, prostate, pancreatic cancer, ovarian cancer, small cell lung cancer and brain cancer.

4. The method according to claim 2 wherein the cancer is a recurring cancer.

5. The method according to claim 2 wherein the cancer is a metastasized or advanced stage cancer.

6. The method according to claim 2 wherein the compound is selected from the group consisting of α-AO2; αBO2; β-AC1; and βAO-1.

7. The method according to claim 1 wherein the cancer is breast cancer.

8. The method according to claim 3 wherein the cancer is breast cancer.

9. The method according to claim 6 wherein the cancer is breast cancer.

10. The method according to claim 1 wherein the tumor stem cell is contacted with the compound at a concentration of 10 μM or greater.

11. The method according to claim 2 wherein the tumor stem cell is contacted with the compound at a concentration of 10 μM or greater.

12. The method according to claim 6 wherein the tumor stem cell is contacted with the compound at a concentration of 10 μM or greater.

13. The method according to claim 7 wherein the tumor stem cell is contacted with the compound at a concentration of 10 μM or greater.

14. The method according to claim 1 wherein the compound is administered in combination with an apoptosis-inducing agent.

15. The method according to claim 2 wherein the compound is administered in combination with an apoptosis-inducing agent.

16. The method according to claim 6 wherein the compound is administered in combination with an apoptosis-inducing agent.

17. The method according to claim 7 wherein the compound is administered in combination with an apoptosis-inducing agent.

18. The method according to claim 1 wherein the cancer is breast cancer.

19. The method according to claim 1 wherein the cancer that is refractory to treatment is treated by killing cancer stem cells.

Assignees

• Univ Manitoba

Inventors

• Arthur Gilbert
• Schweizer Frank
• Samadder Pranati
• Xu Yaozu

Classifications

• A61K31/7028 Primary

  Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07H7/02

  Acyclic radicals · CPC title

• C07H15/04

  attached to an oxygen atom of the saccharide radical · CPC title

• C07H15/14 Primary

  attached to a sulfur, selenium or tellurium atom of a saccharide radical · CPC title